Labcorpvs.Natera
LH vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 1.7× larger than Labcorp by market cap; year to date, Natera leads (+43.1% vs +35.3%).
Side by side
| LH | NTRA | |
|---|---|---|
| Market cap | $26.2B | $44.6B |
| Price | $337.68 | $336.71 |
| Today | −0.5% | +2.7% |
| Return YTD | +35.3% | +43.1% |
| Return 1Y | +22.0% | +97.9% |
| P/E | 26.1 | — |
| P/S | 1.8 | 16.5 |
| P/B | 3.0 | 24.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More LH & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where LH and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →